CRSP
Price
$70.66
Change
-$0.95 (-1.33%)
Updated
Nov 28, 6:59 PM EST
76 days until earnings call
NVAX
Price
$5.73
Change
+$0.27 (+4.95%)
Updated
Nov 28, 6:59 PM EST
90 days until earnings call
Ad is loading...

Compare predictions CRSP vs NVAX

Header iconCRSP vs NVAX Comparison
Open Charts CRSP vs NVAXBanner chart's image
CRISPR Therapeutics AG
Price$70.66
Change-$0.95 (-1.33%)
Volume$970.86K
CapitalizationN/A
Novavax
Price$5.73
Change+$0.27 (+4.95%)
Volume$3.71M
CapitalizationN/A
View a ticker or compare two or three
CRSP vs NVAX Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
CRSP vs. NVAX commentary
Nov 29, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and NVAX is a Hold.

COMPARISON
Comparison
Nov 29, 2023
Stock price -- (CRSP: $70.66 vs. NVAX: $5.73)
Brand notoriety: CRSP: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 95% vs. NVAX: 87%
Market capitalization -- CRSP: $5.69B vs. NVAX: $648.59M
CRSP [@Biotechnology] is valued at $5.69B. NVAX’s [@Biotechnology] market capitalization is $648.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, CRSP is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 0 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 0 bullish, 1 bearish.
  • NVAX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +4.57% price change this week, while NVAX (@Biotechnology) price change was +7.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.02%. For the same industry, the average monthly price growth was +37.81%, and the average quarterly price growth was +8.99%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 13, 2024.

NVAX is expected to report earnings on Feb 27, 2024.

Industries' Descriptions

@Biotechnology (+5.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CRSP with price predictions.
OPEN
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CRSP($5.69B) has a higher market cap than NVAX($649M). CRSP YTD gains are higher at: 73.825 vs. NVAX (-44.261). CRSP has higher annual earnings (EBITDA): -402.88M vs. NVAX (-498.29M). CRSP has more cash in the bank: 1.74B vs. NVAX (651M). NVAX has less debt than CRSP: NVAX (222M) vs CRSP (242M). NVAX has higher revenues than CRSP: NVAX (974M) vs CRSP (170M).
CRSPNVAXCRSP / NVAX
Capitalization5.69B649M876%
EBITDA-402.88M-498.29M81%
Gain YTD73.825-44.261-167%
P/E Ratio20.92N/A-
Revenue170M974M17%
Total Cash1.74B651M267%
Total Debt242M222M109%
FUNDAMENTALS RATINGS
CRSP vs NVAX: Fundamental Ratings
CRSP
NVAX
OUTLOOK RATING
1..100
1854
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
3580
P/E GROWTH RATING
1..100
74100
SEASONALITY SCORE
1..100
1550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (67) in the Biotechnology industry is in the same range as NVAX (88). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for NVAX (80). This means that CRSP’s stock grew somewhat faster than NVAX’s over the last 12 months.

CRSP's P/E Growth Rating (74) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPNVAX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend about 1 month ago
83%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend about 1 month ago
84%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
N/A
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend about 1 month ago
83%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ROM49.030.20
+0.41%
ProShares Ultra Technology
SPTM55.650.02
+0.04%
SPDR® Port S&P 1500 Comps Stk Mkt ETF
TBF24.39-0.03
-0.12%
ProShares Short 20+ Year Treasury
EUDV44.42-0.07
-0.15%
ProShares MSCI Europe Dividend Gr ETF
LCLG37.55-0.10
-0.25%
Logan Capital Broad Innovative Gr ETF

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+4.95%
CRSP - NVAX
47%
Loosely correlated
-1.33%
THRD - NVAX
41%
Loosely correlated
+0.26%
CHRS - NVAX
37%
Loosely correlated
+8.76%
SANA - NVAX
35%
Loosely correlated
N/A
AGEN - NVAX
35%
Loosely correlated
+6.63%
More